Citadel Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Citadel Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-63,000	Closed	-$2.17M	–	11887
2020 Q3	$2.17M	Sell	63,000 -700	-1%	-$14.9K	﹤0.01%	4569
2020 Q2	$1.06M	Buy	63,700 +8,400	+15%	+$143K	﹤0.01%	5725
2020 Q1	$797K	Sell	55,300 -107,000	-66%	-$2.73M	﹤0.01%	5718
2019 Q4	$5.43M	Buy	162,300 +49,400	+44%	+$1.38M	﹤0.01%	2975
2019 Q3	$2.36M	Buy	112,900 +25,200	+29%	+$514K	﹤0.01%	4221
2019 Q2	$1.83M	Buy	87,700 +20,300	+30%	+$418K	﹤0.01%	4670
2019 Q1	$1.51M	Buy	67,400 +9,900	+17%	+$233K	﹤0.01%	4911
2018 Q4	$1.38M	Buy	57,500 +50,000	+667%	+$1.29M	﹤0.01%	4777
2018 Q3	$205K	Sell	7,500 -9,100	-55%	-$257K	﹤0.01%	8183
2018 Q2	$446K	Buy	16,600 +300	+2%	+$9.18K	﹤0.01%	6560
2018 Q1	$519K	Buy	+16,300	New	+$574K	﹤0.01%	5824

Citadel Advisors's AIMT Position: Q4 2020 in Review

Citadel Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 75,551 shares — an estimated $2.6M sold.

Citadel Advisors first reported a position in AIMT in Q2 2016 and held it in 17 quarters. The position peaked at $13.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Citadel Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 75,551 Aimmune Therapeutics shares in Q4 2020, an estimated $2.6M.
Citadel Advisors first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 17 quarters.
Citadel Advisors's Aimmune Therapeutics position peaked at $13.9M in Q3 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.